Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RWJ-333369 for prophylaxis of migraine: randomized double-blind placebo-controlled phase 2 trial
2004-004162-33Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carisbamate in migraine (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Percent reduction in average monthly migraine frequency. Started Sep 2005; status: completed.
02
Drugs
carisbamate
03
Conditions
migraine
Beyond the preview
Go deeper on 2004-004162-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004162-33.